Benzinga - by Avi Kapoor, Benzinga Staff Writer.
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Shares of Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) fell sharply in today’s pre-market trading after the company issued an update on the Phase 3 RAISE Trial and reported preliminary first quarter 2024 financial results.
Marinus Pharma reported Prelim ZTALMY (Ganaxolone) net product revenue of $7.4 million to $7.6 million for the first quarter.
Marinus Pharmaceuticals shares dipped 74.2% to $1.94in pre-market trading.
Here are some big stocks recording losses in today’s pre-market trading session.
- Neumora Therapeutics, Inc. (NASDAQ: NMRA) shares declined 17.1% to $11.25 pre-market trading after the FDA placed a clinical hold on the company's Phase 1 NMRA-266 study.
- Roadzen, Inc. (NASDAQ: RDZN) shares fell 14% to $5.04 in pre-market trading.
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares fell 11.4% to $41.64 in pre-market trading after the company disclosed interim Phase 1/2 data in patients with angelman syndrome after treatment with GTX-102.
- Cogent Biosciences, Inc. (NASDAQ: COGT) shares declined 7.7% to $6.01 in pre-market trading. Cogent Biosciences recently reported preclinical data from CNS-Penetrant ErbB2 Inhibitor Program.
- Polestar Automotive Holding UK PLC (NASDAQ: PSNY) shares fell 7.2% to $1.35 in pre-market trading.
- Molina Healthcare, Inc. (NYSE: MOH) shares fell 7.1% to $350.00 in pre-market trading.
- TORM plc (NASDAQ: TRMD) shares slipped 3.1% to $32.92 in pre-market trading.
Now Read This: Top 3 Tech Stocks That May Explode This Month
Don’t forget to check out our premarket coverage here
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.